AbstractObjective To analyze the invasion characteristics and prognostic factors of patients with Masaoka-Koga stage Ⅲ thymoma. Methods The tumor invasion characteristics of 179 patients who were diagnosed with Masaoka-Koga stage Ⅲ thymoma and treated in Affiliated Cancer Hospital of Zhengzhou University from January 2000 to June 2018 were analyzed retrospectively. According to the treatment methods, all patients were divided into the radical operation group (n=94), palliative operation group (n=39) and simple biopsy group (n=46). The χ2 test was used to compare the classified variables, Kaplan-Meier method was utilized to calculate the cumulative survival rate, log-rank method was used for group comparison and univariate analysis, and Cox’s regression model was used for multivariate analysis. Results Mediastinal pleural invasion (86.0%) was the most common site, followed by pericardium (50.8%), great vessel (40.8%) and lung (36.3%). The proportion of macrovascular invasion in the radical operation group was 14.9%, significantly lower than 79.5% and 60.9% in the palliative surgery group and biopsy group (both P<0.001). Multivariate analysis showed that the nature of operation (P<0.001), age (P=0.011), radiotherapy (P=0.020) were the independent factors affecting overall survival (OS), while nature of operation (P<0.001), age (P=0.004), radiotherapy (P=0.020), number of invasive organs (P=0.023) and pathological type (P=0.016) were the independent factors affecting progress-free survival (PFS). Conclusions For patients with Masaoka-Koga stage Ⅲ thymoma, mediastinal pleura is the most common site of invasion, pericardium, lung and great vessels are also commonly invaded. The invasion of mediastinal pleura, pericardium and lung exerts slight effect on surgical resectability, whereas great vessel involvement can significantly affect surgical resectability. OS and PFS in patients undergoing radical resection are significantly better than those in patients treated with palliative resection and biopsy. Radical resection is the most important factor affecting prognosis.
Corresponding Authors:
Ge Hong, Email:gehong666@126.com
Cite this article:
Fan Chengcheng,Ge Hong,Zhang Yougai et al. Analysis of invasion characteristics and prognostic factors of patients with Masaoka-Koga stage Ⅲ thymoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(1): 29-33.
Fan Chengcheng,Ge Hong,Zhang Yougai et al. Analysis of invasion characteristics and prognostic factors of patients with Masaoka-Koga stage Ⅲ thymoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(1): 29-33.
[1] Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection:a series of 307 patients[J]. J Thorac Cardiovasc Surg, 1996, 112(2):376-384. DOI:10.1016/S0022-5223(96)70265-9. [2] Sonobe M, Nakagawa M, Ichinose M, et al. Thymoma. Analysis of prognostic factors[J]. Jpn J Thorac Cardiovasc Surg, 2001, 49(1):35-41. DOI:10.1007/BF02913121. [3] Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages[J]. Cancer, 1981, 48(11):2485-2492. [4] Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas:modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma[J]. Pathol Int, 1994, 44(5):359-367. [5] Yamada Y, Yoshino I, Nakajima J, et al. Surgical outcomes of patients with stage Ⅲ thymoma in the japanese nationwide database[J]. Ann Thorac Surg, 2015, 100(3):961-967. DOI:10.1016/j.athoracsur.2015.04.059. [6] Detterbeck FC, Stratton K, Giroux D, et al. The IASLC/ITMIG thymic epithelial tumors staging project:proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors[J]. J Thorac Oncol, 2014, 9(9 Suppl 2):S65-72. DOI:10.1097/JTO.0000000000000290. [7] Nicholson AG, Detterbeck FC, Marino M, et al. The IASLC/ITMIG thymic epithelial tumors staging project:proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors[J]. J Thorac Oncol, 2014, 9(9 Suppl 2):S73-80. DOI:10.1097/JTO.0000000000000303. [8] Carter BW, Benveniste MF, Madan R, et al. IASLC/ITMIG Staging system and lymph node map for thymic epithelial neoplasms[J]. Radiographics, 2017, 37(3):758-776. DOI:10.1148/rg.2017160096. [9] Maggi G, Casadio C, Cavallo A, et al. Thymoma:results of 241 operated cases[J]. Ann Thorac Surg, 1991, 51(1):152-156. [10] Myojin M, Choi NC, Wright CD, et al. Stage Ⅲ thymoma:pattern of failure after surgery and postoperative radiotherapy and its implication for future study[J]. Int J Radiat Oncol Biol Phys, 2000, 46(4):927-933. DOI:10.1016/s0360-3016(99)00514-3. [11] Blumberg D, Port JL, Weksler B, et al. Thymoma:a multivariate analysis of factors predicting survival[J]. Ann Thorac Surg, 1995, 60(4):908-913;914. DOI:10.1016/0003-4975(95)00669-c. [12] Fan C, Feng Q, Chen Y, et al. Postoperative radiotherapy for completely resected Masaoka stage Ⅲ thymoma:a retrospective study of 65 cases from a single institution[J]. Radiat Oncol, 2013, 8:199. DOI:10.1186/1748-717X-8-199. [13] Chen YD, Feng QF, Lu HZ, et al. Role of adjuvant radiotherapy for stage Ⅱ thymoma after complete tumor resection[J]. Int J Radiat Oncol Biol Phys, 2010, 78(5):1400-1406. DOI:10.1016/j.ijrobp.2009.09.066. [14] Rimner A, Yao X, Huang J, et al. Postoperative radiation therapy is associated with longer overall survival in completely resected stage Ⅱ and Ⅲ thymoma-an analysis of the international thymic malignancies interest group retrospective database[J]. J Thorac Oncol, 2016, 11(10):1785-1792. DOI:10.1016/j.jtho.2016.06.011. [15] Zhou D, Deng XF, Liu QX, et al. The effectiveness of postoperative radiotherapy in patients with completely resected thymoma:a meta-analysis[J]. Ann Thorac Surg, 2016, 101(1):305-310. DOI:10.1016/j.athoracsur.2015.06.034. [16] Roden AC, Yi ES, Jenkins SM, et al. Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage Ⅰs superior to histopathologic classifications[J]. J Thorac Oncol, 2015, 10(4):691-700. DOI:10.1097/JTO.0000000000000482. [17] Okumura M, Yoshino I, Yano M, et al. Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma[J]. Eur J Cardiothorac Surg, 2019, 56(1):174-181. DOI:10.1093/ejcts/ezz001. [18] Park MS, Chung KY, Kim KD, et al. Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification[J]. Ann Thorac Surg, 2004, 78(3):992-998. DOI:10.1016/j.athoracsur.2004.03.097.
2021, Vol. 30 
